Larimar Therapeutics, Inc.LRMR
What Larimar Therapeutics, Inc. does.
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (“CPP”) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (“FXN”), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA.
We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, also has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, and providing general and administrative support for such operations.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$42.5M | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$165.7M |
| Free cash flow | -$42.3M | -$42.4M | -$27.7M | -$33.6M | -$71.3M | -$113.3M |
More on LRMR.
- Larimar Therapeutics, Inc. summary
- Larimar Therapeutics, Inc. financial statements
- Larimar Therapeutics, Inc. key metrics
- Larimar Therapeutics, Inc. health scores and style box
- Larimar Therapeutics, Inc. earnings
- Larimar Therapeutics, Inc. dividends
- Larimar Therapeutics, Inc. valuation
- Larimar Therapeutics, Inc. ownership and insiders
- Larimar Therapeutics, Inc. peers
Figures from Larimar Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.